Genmab — November 2016
-
Enig Solsen og tak for input.
-
Ved ikke om denne har været på banen. Men viser hvor meget dara betyder for J&J http://seekingalpha.com/article/4026396-value-risk-johnson-and-johnson?app=1&auth_param=1dbtkm:1c3k37o:0c0286fd29bf3aea164e845f5510047c&uprof=46&dr=1
-
-
-
Genmab A/S (GNMSF) Upgraded to “Buy” by Zacks Investment Research
November 25th, 2016 • 0 comments • Filed Under • by ABMN StaffGenmab A/S logoGenmab A/S (OTCMKTS:GNMSF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage currently has a $196.00 price target on the stock. Zacks Investment Research’s price objective would suggest a potential upside of 12.55% from the stock’s current price.
-
Vi er vist tidligere blevet enige om at Zacks maskinelle anbefalinger ikke skal tages seriøst.
-
Genmab får en gevaldig opjustering fra Garnier. Den ryger med i deres maskine.
-
Derfor opjusteringen fredag.
-
Har nogen læst Garnier analysen? Hvad har de i peak sales i knoglemarvskræft og Darzalex i andre indikationer?
-
Jeg har kun læst det som jeg har kunne læse i medierne.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind